MVIR:STO
Medivir AB
1,58 SEK
arrow_downward
−0,88%(−0,014) 1D
6. lis, 17:29:43 GMT+2 · SEK
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za MVIR...
Otvori
1,60 SEK
Najviša
1,65 SEK
Najniža
1,53 SEK
Trž. kap.
1,05 mlr.
Prosj. kol.
1,71 mil.
Količina
0,00
52-tjed. najviša
2,88 SEK
52-tjed. najniža
0,34 SEK
EPS
−0,37 SEK
Dionice u optjecaju
624,18 mil.
Broj djelatnika
6
Otvori
1,60 SEK
Najviša
1,65 SEK
Najniža
1,53 SEK
Trž. kap.
1,05 mlr.
Prosj. kol.
1,71 mil.
Količina
0,00
52-tjed. najviša
2,88 SEK
52-tjed. najniža
0,34 SEK
EPS
−0,37 SEK
Dionice u optjecaju
624,18 mil.
Broj djelatnika
6
Vijesti
Iz web-izvora i od partnera za vijesti
Naslovi.net
·
prije 16 sati
Wall Street: Nasdaq na novom rekordu
SEEbiz.eu
·
prije 3 sata
Wall Street: S&P 500 dosegnuo rekordnu razinu
Simply Wall Street
·
prije 1 sat
What Does Ascendis Pharma (ASND) Gain From Its CNP Patent Settlement?
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Medivir AB – informacije
Glavni izvršni direktorChristine Lind
Zaposlenici6
Osnovano1988
Sjedište-
Sektor-
Web-lokacijamedivir.com